All In Biotech

Drug Trial Radar · NCT00450203

Chemotherapy With or Without Bevacizumab or Lapatinib to Treat Operable Oesophagogastric Cancer

A Randomised Phase II/III Trial of Peri-Operative Chemotherapy With or Without Bevacizumab in Operable Oesophagogastric Adenocarcinoma and A Feasibility Study Evaluating Lapatinib in HER-2 Positive Oesophagogastric Adenocarcinomas and (in Selected Centres) MRI and PET/CT Sub-studies

Last checked: Nov 20, 2026Latest source record: Dec 1, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 1,103 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

1,103

Planned (sponsor's estimate)

Start

Oct 2007

Primary completion

Dec 2017

Study completion Dec 2017

Sponsor

Lead sponsor
Professor David CunninghamGovernment (non-federal)
Sponsor type
Government (non-federal)
Collaborators
Cancer Research UK; Roche Pharma AG; GlaxoSmithKline
First posted
Mar 22, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

RATIONALE: Drugs used in chemotherapy, such as epirubicin, cisplatin, and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, and small molecule tyrosine kinase inhibitors, such as lapatinib, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of tumor cells by blocking blood flow to the tumor. Lapatinib targets a specific growth receptor, HER-2. Chemotherapy together with bevacizumab or lapatinib, in HER-2 positive tumours, may kill more tumor cells. PURPOSE: This randomized phase II/III trial is studying the side effects and how well giving combination chemotherapy together with bevacizumab works compared with combination chemotherapy alone in treating patients with previously untreated stomach cancer, gastroesophageal junction cancer or lower oesophageal cancer that can be removed by surgery. The feasibility study is studying the safety of adding lapatinib to chemotherapy in patients with HER-2 positive previously untreated stomach cancer, gastroesophageal junction cancer or lower oesophageal cancer that can be removed by surgery. The feasibility study will also assess the feasibility of timely HER-2 testing and estimate the HER-2 positivity rate in this patient population.

Conditions

  • Oesophagogastric Cancer

Interventions

  • bevacizumabBiological

    7.5mg/kg IV Day 1 of each 21 cycle of chemotherapy (6 cycles) plus day 1 of each maintenance dose every 21 days for 6 doses.

  • capecitabineDrug

    dose banded as based on patient BSA. Oral dose given twice a day during each 21 day cycle of chemotherapy (6 cycles in total)

  • cisplatinDrug

    60mg/m2 IV day one of each 21 day cycle of chemotherapy (6 cycles in total)

  • EpirubicinDrug

    50mg/m2 IV day one of each 21 day cycle of chemotherapy (6 cycles in total)

  • adjuvant therapyProcedure

    3 cycles of ECX chemotherapy post operatively

  • conventional surgeryProcedure

    Surgery undertaken after 3 cycles of pre-operative chemotherapy. Followed by 3 cycles of chemotherapy.

  • neoadjuvant therapyProcedure

    3 cycles of pre-operative ECX chemotherapy.

  • LapatinibDrug

    1250mg/day Day 1-21 of each cycle of chemotherapy (6 cycles) plus day 1-21 of each maintenance course every 21 days for 6 doses.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. SafetyTime frame: at the end of phase II and phase III
  2. EfficacyTime frame: end of trial
  3. Overall survivalTime frame: end of trial

Locations

41 sites in 1 country. Site status is shown where the registry gives one.

  • Basingstoke and North Hampshire Hospital

    Basingstoke, United Kingdom · Recruiting

  • Birmingham Heartlands Hospital

    Birmingham, United Kingdom · Recruiting

  • Castle Hill Hospital

    Cottingham, United Kingdom · Recruiting

  • University Hospitals Coventry and Warwickshire

    Coventry, United Kingdom · Recruiting

  • Beatson West of Scotland Cancer Centre

    Glasgow, United Kingdom · Recruiting

  • St James Hospital

    Leeds, United Kingdom · Recruiting

  • Leicester Royal Infirmary

    Leicester, United Kingdom · Recruiting

  • Norfolk and Norwich University Hospital

    Norwich, United Kingdom · Recruiting

  • Churchill Hospital

    Oxford, United Kingdom · Recruiting

  • Queens Hospital

    Romford, United Kingdom · Recruiting

  • Weston Park

    Sheffield, United Kingdom · Recruiting

  • Great Western Hospital

    Swindon, United Kingdom · Recruiting

  • Musgrove Park Hospital

    Taunton, United Kingdom · Recruiting

  • Royal Bournemouth Hospital

    Bournemouth, England, United Kingdom · Recruiting

  • Bradford Royal Infirmary

    Bradford, England, United Kingdom · Active not recruiting

  • Bristol Haematology and Oncology Centre

    Bristol, England, United Kingdom · Recruiting

  • Addenbrooke's Hospital

    Cambridge, England, United Kingdom · Active not recruiting

  • Cumberland Infirmary

    Carlisle, England, United Kingdom · Active not recruiting

  • Doncaster Royal Infirmary

    Doncaster, England, United Kingdom · Recruiting

  • St. Luke's Cancer Centre at Royal Surrey County Hospital

    Guildford, England, United Kingdom · Recruiting

  • Huddersfield Royal Infirmary

    Huddersfield, West Yorks, England, United Kingdom · Recruiting

  • Leeds Cancer Centre at St. James's University Hospital

    Leeds, England, United Kingdom · Recruiting

  • Lincoln County Hospital

    Lincoln, England, United Kingdom · Active not recruiting

  • Aintree University Hospital

    Liverpool, England, United Kingdom · Recruiting

  • Saint Bartholomew's Hospital

    London, England, United Kingdom · Recruiting

  • St. George's Hospital

    London, England, United Kingdom · Active not recruiting

  • St. Mary's Hospital

    London, England, United Kingdom · Active not recruiting

  • Mid Kent Oncology Centre at Maidstone Hospital

    Maidstone, England, United Kingdom · Recruiting

  • Christie Hospital

    Manchester, England, United Kingdom · Recruiting

  • Clatterbridge Centre for Oncology

    Merseyside, England, United Kingdom · Recruiting

  • Northern Centre for Cancer Treatment at Newcastle General Hospital

    Newcastle upon Tyne, England, United Kingdom · Recruiting

  • Derriford Hospital

    Plymouth, England, United Kingdom · Active not recruiting

  • Dorset Cancer Centre

    Poole Dorset, England, United Kingdom · Active not recruiting

  • Berkshire Cancer Centre at Royal Berkshire Hospital

    Reading, England, United Kingdom · Recruiting

  • Rochdale Infirmary

    Rochdale, England, United Kingdom · Active not recruiting

  • Salisbury District Hospital

    Salisbury, England, United Kingdom · Recruiting

  • Wexham Park Hospital

    Slough, Berkshire, England, United Kingdom · Recruiting

  • Southampton General Hospital

    Southampton, England, United Kingdom · Recruiting

  • Royal Marsden - Surrey

    Sutton, England, United Kingdom · Recruiting

  • Aberdeen Royal Infirmary

    Aberdeen, Scotland, United Kingdom · Recruiting

Showing 40 of 41 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.